SCHEMBL4127398

SCHEMBL4127398

COc1ccc(-c2cc(F)cc(F)c2)cc1/C=C1/SC(Nc2ccc(CC(=O)O)cc2)=NC1=O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 4/20 0.42
NR1H4 Q96RI1 1/20 0.41
PDE4B Q07343 7/20 0.41
PDE4D Q08499 7/20 0.41
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
MCL1 Q07820 1/20 0.39
S1PR1 P21453 1/20 0.37
CISD1 Q9NZ45 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4127402 1.00 ALOX5 (0.42) ALOX5NR1H4PDE4BPDE4DTDP1
SCHEMBL4140928 0.89 PDE4B (0.41) ALOX5PDE4BPDE4DTDP1MEN1
SCHEMBL4140926 0.89 PDE4B (0.41) ALOX5PDE4BPDE4DTDP1MEN1
SCHEMBL4634765 0.79 ALOX5 (0.52) ALOX5NR1H4PDE4BPDE4DTDP1
SCHEMBL4634758 0.79 ALOX5 (0.52) ALOX5NR1H4PDE4BPDE4DTDP1
SCHEMBL4122280 0.78 PDE4B (0.42) ALOX5NR1H4PDE4BPDE4DTDP1
SCHEMBL4122284 0.78 PDE4B (0.42) ALOX5NR1H4PDE4BPDE4DTDP1
SCHEMBL4127729 0.78 KMT2A (0.49) ALOX5TDP1MEN1HPGDKMT2A
SCHEMBL4131441 0.78 KMT2A (0.51) ALOX5TDP1MEN1HPGDKMT2A
SCHEMBL4136345 0.78 KMT2A (0.51) ALOX5TDP1MEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALOX5 3505/4885NR1H4 2884/4885PDE4B 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.